Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898364 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.
A Phase 1 study of Pompe Disease and Glycogen Storage Disease Type II (GSD-II), sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 17
- Study locations
NCT01898364 is a Phase 1 study of Pompe Disease and Glycogen Storage Disease Type II (GSD-II) that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 24 participants, below the 231-participant average among 14 other Pompe Disease trials with a reported enrollment target (90% lower). The trial reports 17 study locations across 8 states.
The verdict
NCT01898364, a Phase 1 study of Pompe Disease and Glycogen Storage Disease Type II (GSD-II), has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 17
- Study locations
Study Summary
Primary Objective: To evaluate the safety and tolerability of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. Secondary Objective: To evaluate the pharmacokinetics, pharmacodynamics of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. To evaluate the effect of neoGAA on exploratory efficacy endpoints in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients.
Conditions Studied
Interventions
- DRUG GZ402666
Study Locations (17)
Other
- Investigational Site Number 056001 - Leuven
- Investigational Site Number 208001 - København Ø
- Investigational Site Number 250001 - Marseille
- Investigational Site Number 250003 - Nice
- Investigational Site Number 250002 - Paris
- Investigational Site Number 276003 - Mainz
- Investigational Site Number 276001 - München
- Investigational Site Number 276002 - Münster
- Investigational Site Number 528001 - Rotterdam
- Investigational Site Number 826003 - Newcastle upon Tyne
Arizona
- Investigational Site Number 840006 - Phoenix
Florida
- Investigational Site Number 840010 - Jacksonville
Kansas
- Investigational Site Number 840001 - Kansas City
Missouri
- Investigational Site Number 840008 - St Louis
North Carolina
- Investigational Site Number 840002 - Durham
Texas
- Investigational Site Number 840009 - Dallas
Virginia
- Investigational Site Number 840003 - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2013-08-19 |
| Est. Completion | 2015-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898364
The ClinicalTrials.gov registry entry for NCT01898364 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 14 other Pompe Disease trials with a reported enrollment target (90% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pompe Disease appearing as the primary indexed condition, and to 1 intervention - of which GZ402666 is the first listed.
NCT01898364 reports 17 study locations spanning 8 distinct geographic areas - top geographies include Other, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT01898364 about?
NCT01898364 is a clinical study titled "Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.". Primary Objective: To evaluate the safety and tolerability of neoGAA in treatment naïve and alglucosidase alfa treated late-onset Pompe disease patients. Secondary Objective: To evaluate the pharmacokinetics, pharmacodynamics of neoGAA in treatment naïve and alglucosidase alfa treated late-onset ...
What is the current status of trial NCT01898364?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2013-08-19. Estimated completion is 2015-02-25.
What conditions does trial NCT01898364 study?
This clinical trial studies the following conditions: Pompe Disease, Glycogen Storage Disease Type II (GSD-II), Acid Maltase Deficiency.
What interventions are being tested in trial NCT01898364?
The interventions under investigation include: GZ402666 (DRUG).
Who is sponsoring clinical trial NCT01898364?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01898364 being conducted?
This trial has 17 study locations across Arizona, Florida, Kansas, Missouri, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pompe Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
ACTIVE NOT RECRUITING · Phase 1
-
AAV2/8-LSPhGAA (ACTUS-101) in Late-Onset Pompe Disease
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase to Treat Pompe Disease
COMPLETED · Phase 1
-
Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)
RECRUITING · Phase 2
-
Cognitive and Neurological Pathologies in Pompe Disease
RECRUITING
-
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.